

(12) UK Patent Application (19) GB (11) 2 188 639 (13) A
 (43) Application published 7 Oct 1987


<p>(21) Application No 8707971</p> <p>(22) Date of filing 3 Apr 1987</p> <p>(30) Priority data</p> <p>(31) 848671 (32) 4 Apr 1986 (33) US</p>	<p>(51) INT CL⁴ C12N 15/00 G01N 33/569</p> <p>(52) Domestic classification (Edition I) C3H 402 406 409 431 432 684 B7P G1B 103 104 301 402 427 522 AD AE U1S 1296 1337 G1B G3H</p> <p>(56) Documents cited EP A10187041 WO A1 85/04903 WO A1 86/06414</p> <p>(58) Field of search C3H G1B Selected US specifications from IPC sub-classes C12N G01N</p>
<p>(71) Applicant F. Hoffmann-La Roche & Co. Aktiengesellschaft, (Incorporated in Switzerland), 124-184 Grenzacherstrasse, CH-4002 Basle, Switzerland</p> <p>(72) Inventors Robert Mitchell Crowl, Daru Young</p> <p>(74) Agent and/or Address for Service Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA</p>	

(54) Expression and purification of an HTLV-III GAG/ENV gene protein


(57) The present invention provides methods and compositions for the cloning and expression of plasmids bearing genes encoding a novel protein derived from HTLV-III. This protein, which is called the gag/env protein and which contains antigenic determinants from both the core and envelope proteins of HTLV-III, can be purified to homogeneity and used as the basis for diagnostic tests to detect the presence of antibodies against viruses associated with AIDS or the viruses themselves in human sera and other biological fluids. The gag/env protein may also be formulated for use as a vaccine for protection against AIDS through prophylactic immunization.

GB 2 188 639 A

FIGURE I



gag 15-512



gag 15-436/env 467-640, Δ514-524

FIGURE 2

2188639

Clal

ATG AAT AGA ATT CGG ATC CAT CGA TGG GAA AAA ATT CGG TTA AGG CCA GGG GGA
 MET Asn Arg Ile Arg Ile His Arg Trp Glu Lys Ile Arg Leu Arg Pro Gly Gly
 15 gag--->

AAG AAA AAA TAT AAA TTA AAA CAT ATA GTA TGG GCA AGC AGG GAG CTA GAA CGA
 Lys Lys Lys Tyr Lys Leu Lys His Ile Val Trp Ala Ser Arg Glu Leu Glu Arg

TTC GCA GTT AAT CCT GGC CTG TTA GAA ACA TCA GAA GGC TGT AGA CAA ATA CTG
 Phe Ala Val Asn Pro Gly Leu Leu Glu Thr Ser Glu Gly Cys Arg Gln Ile Leu

GGA CAG CTA CAA CCA TCC CTT CAG ACA GGA TCA GAA GAA CTT AGA TCA TTA TAT
 Gly Gln Leu Gln Pro Ser Leu Gln Thr Gly Ser Glu Glu Leu Arg Ser Leu Tyr

AAT ACA GTA GCA ACC CTC TAT TGT GTG CAT CAA AGG ATA GAG ATA AAA GAC ACC
 Asn Thr Val Ala Thr Leu Tyr Cys Val His Gln Arg Ile Glu Ile Lys Asp Thr

AAG GAA GCT TTA GAC AAG ATA GAG GAA GAG CAA AAC AAA AGT AAG AAA AAA GCA
 Lys Glu Ala Leu Asp Lys Ile Glu Glu Glu Gln Asn Lys Ser Lys Lys Lys Ala

CAG CAA GCA GCA GCT GAC ACA GGA CAC AGC AGT CAG GTC AGC CAA AAT TAC CCT
 Gln Gln Ala Ala Ala Asp Thr Gly His Ser Ser Gln Val Ser Gln Asn Tyr Pro

ATA GTG CAG AAC ATC CAG GGG CAA ATG GTA CAT CAG GCC ATA TCA CCT AGA ACT
 Ile Val Gln Asn Ile Gln Gly Gln MET Val His Gln Ala Ile Ser Pro Arg Thr

TTA AAT GCA TGG GTA AAA GTA GTA GAA GAG AAG GCT TTC AGC CCA GAA GTA ATA
 Leu Asn Ala Trp Val Lys Val Val Glu Glu Lys Ala Phe Ser Pro Glu Val Ile

CCC ATG TTT TCA GCA TTA TCA GAA GGA GCC ACC CCA CAA GAT TTA AAC ACC ATG
 Pro MET Phe Ser Ala Leu Ser Glu Gly Ala Thr Pro Gln Asp Leu Asn Thr MET

CTA AAC ACA GTG GGG GGA CAT CAA GCA GCC ATG CAA ATG TTA AAA GAG ACC ATC
 Leu Asn Thr Val Gly Gly His Gln Ala Ala MET Gln MET Leu Lys Glu Thr Ile

AAT GAG GAA GCT GCA GAA TGG GAT AGA GTA CAT CCA GTG CAT GCA GGG CCT ATT
 Asn Glu Glu Ala Ala Glu Trp Asp Arg Val His Pro Val His Ala Gly Pro Ile

GCA CCA GGC CAG ATG AGA GAA CCA AGG GGA AGT GAC ATA GCA GGA ACT ACT AGT
 Ala Pro Gly Gln MET Arg Glu Pro Arg Gly Ser Asp Ile Ala Gly Thr Thr Ser

ACC CTT CAG GAA CAA ATA GGA TGG ATG ACA AAT AAT CCA CCT ATC CCA GTA GGA
 Thr Leu Gln Glu Gln Ile Gly Trp MET Thr Asn Asn Pro Pro Ile Pro Val Gly

GAA ATT TAT AAA AGA TGG ATA ATC CTG GGA TTA AAT AAA ATA GTA AGA ATG TAT
 Glu Ile Tyr Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys Ile Val Arg MET Tyr

AGC CCT ACC AGC ATT CTG GAC ATA AGA CAA GGA CCA AAA GAA CCT TTT AGA GAC
 Ser Pro Thr Ser Ile Leu Asp Ile Arg Gln Gly Pro Lys Glu Pro Phe Arg Asp

TAT GTA GAC CGG TTC TAT AAA ACT CTA AGA GCC GAG CAA GCT TCA CAG GAG GTA
 Tyr Val Asp Arg Phe Tyr Lys Thr Leu Arg Ala Glu Gln Ala Ser Gln Glu Val

FIGURE 2 (continued)

AAA AAT TGG ATG ACA GAA ACC TTG TTG GTC CAA AAT GCG AAC CCA GAT TGT AAG
Lys Asn Trp MET Thr Glu Thr Leu Leu Val Gln Asn Ala Asn Pro Asp Cys Lys

ACT ATT TTA AAA GCA TTG GGA CCA GCG GCT ACA CTA GAA GAA ATG ATG ACA GCA
Thr Ile Leu Lys Ala Leu Gly Pro Ala Ala Thr Leu Glu Glu MET MET Thr Ala

TGT CAG GGA GTA GGA GGA CCC GGC CAT AAG GCA AGA GTT TTG GCT GAA GCA ATG
Cys Gln Gly Val Gly Gly Pro Gly His Lys Ala Arg Val Leu Ala Glu Ala MET

AGC CAA GTA ACA AAT ACA GCT ACC ATA ATG ATG CAG AGA GGC AAT TTT AGG AAC
Ser Gln Val Thr Asn Thr Ala Thr Ile MET MET Gln Arg Gly Asn Phe Arg Asn

CAA AGA AAG ATG GTT AAG TGT TTC AAT TGT GGC AAA GAA GGG CAC ACA GCC AGA
Gln Arg Lys MET Val Lys Cys Phe Asn Cys Gly Lys Glu Gly His Thr Ala Arg

AAT TGC AGG GCC CCT AGG AAA AAG GGC TGT TGG AAA TGT GGA AAG GAA GGA CAC
Asn Cys Arg Ala Pro Arg Lys Lys Gly Cys Trp Lys Cys Gly Lys Glu Gly His

BgIII

CAA ATG AAA GAT TGT ACT GAG AGA CAG GCT AAT TTT TTA GGG AAG ATC TTC AGA
Gln MET Lys Asp Cys Thr Glu Arg Gln Ala Asn Phe Leu Gly Lys Ile Phe Arg
<---gag 436/467 env--->

CCT GGA GGA GGA CAT ATG AGG GAC AAT TGG AGA AGT GAA TTA TAT AAA TAT AAA
Pro Gly Gly Gly Asp MET Arg Asp Asn Trp Arg Ser Glu Leu Tyr Lys Tyr Lys

GTA GTA AAA ATT GAA CCA TTA GGA GTA GCA CCC ACC AAG GCA AAG AGA AGA GTG
Val Val Lys Ile Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Lys Arg Arg Val

GTG CAG AGA GAA AAA AGA GCA GTG GCA GCA GGA AGC ACT ATG GGC GCA GCG TCA
Val Gln Arg Glu Lys Arg Ala Val Ala Ala Gly Ser Thr MET Gly Ala Ala Ser

ATG ACG CTG ACG GTA CAG GCC AGA CAA TTA TTG TCT GGT ATA GTG CAG CAG CAG
MET Thr Leu Thr Val Gln Ala Arg Gln Leu Leu Ser Gly Ile Val Gln Gln Gln

AAC AAT TTG CTG AGG GCT ATT GAG GCG CAA CAG CAT CTG TTG CAA CTC ACA GTC
Asn Asn Leu Leu Arg Ala Ile Glu Ala Gln Gln His Leu Leu Gln Leu Thr Val

TGG GGC ATC AAG CAG CTC CAG GCA AGA ATC CTG GCT GTG GAA AGA TAC CTA AAG
Trp Gly Ile Lys Gln Leu Gln Ala Arg Ile Leu Ala Val Glu Arg Tyr Leu Lys


GAT CAA CAG CTC CTG GGG ATT TGG GGT TGC TCT GGA AAA CTA CTT TGC ACC ACT
Asp Gln Gln Leu Leu Gly Ile Trp Gly Cys Ser Gly Lys Leu Leu Cys Thr Thr

GCT GTG CCT TGG AAT GCT AGT TGG AGT AAT AAA TCT CTG GAA CAG ATT TGG AAT
Ala Val Pro Trp Asn Ala Ser Trp Ser Asn Lys Ser Leu Glu Gln Ile Trp Asn

HindIII

CAC ACG ACG TGG ATG GAG TGG GAC AGA GAA ATT AAC AAT TAC ACA AGC TTT AAT
His Thr Thr Trp MET Glu Trp Asp Arg Glu Ile Asn Asn Tyr Thr Ser Phe Asn
640

GCG GTA GTT TAT CAC AGT TAA
Ala Val Val Tyr His Ser .

Figure 3

SPECIFICATION

Expression and purification of an HTLV-III gag/env gene protein

- 5 The present invention relates to a protein designated gag/env, which comprises the core protein (gag) and the envelope protein (env) of the HTLV-III virus, the etiologic agent for acquired immune deficiency syndrome (AIDS). This protein is produced through organic synthetic methods or through the use of recombinant DNA techniques in which the requisite gene sequences are inserted by means of a suitable DNA
- 10 vector into a compatible unicellular host organism.
- This invention further relates to the isolation and purification of the gag/env protein and to methods for the detection of AIDS antibodies or viruses in human sera or other biological fluids and for the immunoprophylactic protection of human beings against AIDS, based on the use of the protein.
- In 1985 nearly 8,000 people were diagnosed as having AIDS, and the number has been steadily increasing. 15 Fifteen thousand more cases are expected to be diagnosed in 1986, and the number of cases may well double again in 1987 [New York Times Magazine, March 2, 1986, p. 42]. AIDS has been characterized by the onset of severe opportunistic infections secondary to an effect on the body's immune system [Gottlieb et al., New Eng. J. Med. 305: 1425 (1981)]. The disease has been found in male homosexuals, patients receiving blood products, intravenous drug addicts and individuals originating from Haiti and Central Africa [Piot et al., 20 Lancet 11:65 (1984)].
- The causative agent was suspected to be of viral origin because the epidemiological pattern of AIDS was consistent with that of a transmissible disease. At least three retroviruses have been isolated from cultured T-cells of several patients with AIDS, or from white blood cells of persons at risk for the disease. A novel human retrovirus called lymphadenopathy-associated virus (LAV) was discovered, and its properties were 25 consistent with an etiological role in AIDS. That virus was isolated from a patient with lymphadenopathy and hence the name [Montagnier et al., in Human T-Cell Leukemia/Lymphoma Virus, R.C. Gallo et al. eds., Cold Spring Harbor Laboratory, pp. 363-370 (1984)].
- Other human retroviruses, specifically two subgroups of the human T-cell leukemia/lymphoma/lymphotropic virus, types I [Poesz et al., Proc. Natl. Acad. Sci. U.S.A. 77:7415 (1980)] 30 and III [Popovic et al., Science 224:497 (1984)] have also been isolated. Still another virus, called the AIDS-associated retrovirus (ARV), has been proposed as the causative agent [Levy et al., Science 225:840 (1984)]. Both the HTLV-III and ARV retroviruses display biological and seroepidemiological properties similar to LAV [Levy et al., supra, Popovic et al., supra]. Thus, at least three retroviruses have been postulated to be the etiologic agent or AIDS: LAV, ARV, and HTLV-III. For this application, these viruses will be collectively 35 referred to as the AIDS viruses. Because HTLV-III is the prototypic virus for this group, it will be understood that the term "antigenic determinant corresponding to the sequences of a protein of an HTLV-III virus" actually refers to the sequences of the proteins of any of the AIDS viruses.
- One reason for the difficulty in determining the true etiologic agent of AIDS was cross-reactivity of various retroviral antigens with serum samples from AIDS patients. For example, serum samples from AIDS patients 40 have been shown to react with antigens of both HTLV-I [Essex et al., Science 220:859 (1983)] and HTLV-III [Samgadharan et al., Science 224:506 (1984)]. Envelope gene products of HTLV demonstrated antigenicities that were cross-reactive with antibodies in sera from adult T-cell leukemia patients [Kiyokawa et al., Proc. Natl. Acad. Sci. U.S.A. 81:6202 (1984)]. Adult T-cell leukemias (ATL) differ from acquired immune deficiency syndrome (AIDS) in that HTLV-I causes T-cell malignancies that are characterized by the uncontrolled growth 45 of T-cells. In AIDS, instead of cell growth there is cell death. In fact this cytopathic characteristic of HTLV-III was critical to ultimately determining the specific retroviral origin of the disease.
- The etiologic agent of AIDS was isolated by the use of immortalized human neoplastic T cell lines (HT) infected with the cytopathic retrovirus characteristic of AIDS, isolated from AIDS afflicted patients. Seroepidemiological assays using this virus showed a complete correlation between AIDS and the presence 50 of antibodies to HTLV-III viral antigens [Montagnier et al., supra; Samgadharan et al., supra; Schüpbach et al., Science 224:503 (1984)]. In addition, nearly 85% of patients with lymphadenopathy syndrome and a significant proportion of asymptomatic homosexual men in AIDS endemic areas were also found to carry circulating antibodies to HTLV-III. Taken together, these data implicate HTLV-III as the principal etiologic agent for AIDS.
- 55 Until the successful culturing of the AIDS virus using the H-9 cell line, the env AIDS protein of the AIDS virus had not been isolated, characterized or synthesized. This in major part was due to the fact that the virus is cytopathic, and isolation of the virus was thus not possible [Popovic et al., supra]. Once a human T-cell line that was resistant to the cytopathic effects of the virus was discovered, however, the molecular cloning of AIDS proviral DNA could be carried out.
- 60 The need for sensitive and rapid methods for the diagnosis of AIDS in human blood and in other biological fluids and for a method to prevent the disease by vaccination is very great. Virtually all of the assays and tests presently available are fraught with errors. In fact, the Center for Disease Control (CDC) has indicated that presently available tests should be used solely for screening units of blood for the presence of antibodies to HTLV-III. The CDC has even gone further by stating that the presently available enzyme-linked 65 immunosorbent assay (ELISA) tests should not be used for the general screening of high risk populations or

as a diagnostic test for AIDS [Federal Register 50(48):9909, March 12, 1985].

The errors in previously used AIDS tests have been traced to the failure to use a specific antigenic protein of the etiologic agent for AIDS. The previously used proteins were derived from a viral lysate. Since the lysate is made from human cells infected with the virus, i.e. the cells used to grow the virus, the lysate will contain human proteins as well as viral proteins. Thus preparation of a pure antigen of viral protein is very difficult. The antigens used until now have thus produced both false positive and false negative results [Budiansky, Nature 312: 583 (1984)]. The errors caused by the use of such lysate proteins/peptides could be avoided by using a composition for binding AIDS antibodies which is substantially free of the non-AIDS specific proteins. Compositions of substantially pure AIDS envelope and core protein can be used as antigens.

Both the envelope and core proteins of HTLV-III have conserved antigenic determinants which would permit their use to screen for, diagnose and/or provide protection by vaccination against the AIDS viruses. And individuals that have been exposed to HTLV-III and who may thus be at risk to contract AIDS or who have the disease can be identified by the presence in their blood of antibodies to the viral core protein (gag) and/or the envelope protein (env), [Sarnagadharan et al., Science 224:506 (1984)].

The availability of a reliable and sensitive test for the presence in blood or in other biological fluids of the AIDS virus itself, or of particles therefrom, is also important. Groopman et al. [Blood 66:742 (1985)] have reported that antibodies against AIDS viruses are not always present in the blood of AIDS victims. Groopman et al. examined one patient with AIDS and another with related disorders (ARC) from whom blood samples were taken which were antibody negative but from which HTLV-III could be cultured.

Recombinant DNA technology has recently been applied to the AIDS problem. The molecular cloning and expression of the env gene from HTLV-III has been reported [Crowl et al., Cell 41:979 (1985); Chang et al., Biotechnology 3:905 (1985)]. Dowbenko et al. [Proc. Natl. Acad. Sci. U.S.A. 82:7748 (1985)] have expressed the HTLV-III core protein in E. coli.

Through the use of such genetic engineering techniques, purified viral antigens that are safe, reliable and less costly to produce have become available. Even more advantageous, however, would be the availability of a viral protein having antigenic determinants that are present on both the env and the gag proteins. Such a protein would be an exceptionally powerful tool for the detection of AIDS antibodies, and it could serve as the basis for a variety of sensitive diagnostic tests and for a possible vaccine against the AIDS virus.

Therefore a novel protein, designat gag/env, having an amino acid sequence corresponding to at least one antigenic determinant of a HTLV-III gag protein and of a HTLV-III env protein has been provided which permits to screen for, diagnose and/or protect by vaccination against the AIDS virus. The novel gag/env protein can be represented by all or part of the amino acid sequence shown in Figure 2 or a functional equivalent thereof.

The invention further provides the requisite DNA sequences coding for the gag/env polypeptide of the present invention, recombinant vectors containing such DNA sequences, and unicellular organisms useful in the production through recombinant DNA technology of the gag/env protein of the present invention as well as processes for the manufacture of such DNA sequences, recombinant vectors and unicellular organisms. In addition methods are described for the expression and isolation of the gag/env protein of the present invention. The gag/env protein thus produced may be utilized by the methods of this invention for a number of important immunological processes.

Through use as a diagnostic reagent, the gag/env protein can be used to detect the presence of antibodies against AIDS viruses in human sera or in other biological fluids such as tears, semen, vaginal secretions and saliva. Because the protein can be prepared in a homogeneous form, problems of non-specific reactions which have plagued the use of diagnostic reagents based upon relatively crude HTLV-III viral protein isolates in the past are eliminated.

Used as an immunogen, the gag/env protein can be employed to produce antibodies in animals against the antigenic determinants contained therein. Such antibodies can in turn be used, in conjunction with the gag/env protein which has been suitably labeled, in a radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA) to detect the presence of HTLV-III viruses or particles therefrom in human serum or in other biological fluids such as tears, semen, vaginal secretions and saliva. Particles (or fragments) that could be detected by these methods include of course pieces of the viral core or envelope proteins.

By incorporation into a suitable vaccine formulation, the gag/env protein of the present invention may further be used to combat the spread of AIDS through prophylactic immunization.

There are important advantages to using the gag/env protein of the invention, compared to using separate gag and env proteins. The env protein itself is very insoluble, which makes purification difficult. Combination of the two proteins results in a product that is more easily solubilized and therefore more easily purified. Large-scale production and purification are also simplified, of course, since only a single compound must be isolated. Finally, the gag/env protein makes possible the development of a diagnostic kit which works better in an antigen sandwich assay than would separate gag and env proteins.

Although the gag/env protein was derived from HTLV-III, it must be understood that the diagnostic and immunoprophylactic methods described herein are applicable to the detection of any of the other viral agents which have been implicated in or associated with AIDS such as lymphadenopathy-associated virus (LAV) and AIDS-associated retrovirus (ARV). This is because Crowl et al. [Cell 41: 979 (1985)] have shown that proteins from these viral agents are immunologically related to those of HTLV-III and have amino acid

sequence segments in common.

The present invention may be more readily understood on the basis of the following detailed description when considered in connection with the following figures, wherein

Figure 1 is a schematic representation of expression plasmids which directs the synthesis of gag (upper drawing) and gag/env (lower drawing) proteins. Restriction endonuclease sites delineating the gag and env genes are shown, and the cross-hatched region denotes the env segment of the gag/env fusion gene. In both plasmids transcription is under the control of the λ P_L promoter, and translation initiation signals are from plasmid pEV-vrf2;

Figure 2 shows the nucleic acid sequence of the gag/env fusion gene (with selected position numbers and restriction endonuclease sites indicated) and the amino acid sequence of the gag/env protein predicted therefrom; and

Figure 3 shows the results of SDS-polyacrylamide gel electrophoretic analysis of the gag/env protein produced in *E. coli*. Panel 1 shows Coomassie blue-stained total cell proteins from cells harboring the recombinant plasmid carrying the gag/env fusion gene and from control cells. Panels 2 and 3 are Western blots of total cell protein probed with either rabbit antibodies against env peptide 500-511 (panel 2) or sheep antibodies against gag p24 (panel 3). The immune complexes in panels 2 and 3 were visualized by a second antibody labeled with horseradish peroxidase. In all three panels g/e refers to the gag/env protein, and c refers to a negative control sample used to show specificity. The mobilities of molecular weight standards (in kD) are shown, and the position of the gag/env protein band in the gels is indicated by the arrows.

The methods of this invention entail a number of steps which, in logical sequence, include (1) identification and isolation of the genes encoding the gag and env proteins or fragments thereof, (2) insertion of these genes or gene fragments into an appropriate cloning vehicle to produce a recombinant vector containing a gag/env fusion gene, (3) transfer of the recombinant cloning vehicle into a compatible single cell host organism, (4) selection and growth of properly modified hosts that can replicate and express the inserted gene sequences, (5) identification and purification of the gene product, (6) use of the gene product to detect antibodies against HTLV-III or related viruses or as an immunogen to produce antibodies that can in turn be used to detect the viruses themselves or fragments therefrom in human sera or in other biological fluids, and (7) use of the gag/env protein in a vaccine formulation for possible immunoprophylactic protection against AIDS.

Isolated HTLV-III virions could be used as the source for both the gag and the env genes of the invention. For example, Dowbenko et al. [Proc. Natl. Acad. Sci. U.S.A. 82:7748 (1985)] have used a 2.2 kilobase (kb) fragment from the 5' region of the viral genome as a source of the gag gene. Alternatively, genomic DNA from cells into which the proviral genome of HTLV-III has been integrated can be the gene source [Shaw et al., Science 226:1165 (1984)]. Cowl et al. [Cell 41:979 (1985)] have used such genomic DNA from H9 cells infected with HTLV-III to obtain the env gene.

Alternatives to the isolation of the gag and env genes include but are not limited to the chemical synthesis of the gene sequences and the preparation of DNA that is complementary to the messenger RNA produced from the genes.

Regardless of its source, DNA encoding the gag and env proteins can be cloned into bacteria, and clones containing the gag or env genes can be identified by methods that are well known in the art. For example, complimentary DNA (cDNA) probes could be prepared for the genes and used to detect clones bearing the genes through hybridization techniques.

In a preferred embodiment of the present invention, a genomic library constructed by XbaI digestion of the DNA of the HTLV-III-infected H9 cells described above was cloned using a phase λ vector, and clones bearing the HTLV-III proviral genome were identified by hybridization with HTLV-III cDNA. One such clone was designated λ HXB-3, and a 1700 base-pair fragment encoding most of the gag precursor protein was isolated by ClaI/HincII digestion of the DNA from this clone.

The immediate source of env gene sequences used in the preferred embodiment of the invention was a derivative of plasmid pEV3/env 44-640 that had env codons corresponding to residues 514-524 deleted. This deletion surprisingly results in a significant increase in the expression of the env gene. Env sequences containing codons 467 to 640 were obtained by the BglII/HindIII cleavage of plasmid pEV3/env 44-640.

Once identified and isolated, the gag and env genes of HTLV-III are inserted into an appropriate expression vehicle which contains the elements necessary for transcription and translation of the inserted gene sequences. Useful cloning vehicles may consist of segments of chromosomal, nonchromosomal and synthetic DNA sequences such as various known bacterial plasmids, phage DNA, combinations of plasmids and phage DNAs such as plasmids which have been modified to employ phage DNA or other expression control sequences, or yeast plasmids. Specific cloning vehicles which could be used include but are not limited to the pEV-vrf plasmids (pEV-vrf1, -2 and -3), SV40, adenovirus, yeast, lambda gt-WES-lambda B, Charon 4A and 28, Lambda-gt-1-lambda B, M13-derived vectors such as pUC8, 9, 18 and 19, pBR313, 322 and 325, pAC105, pVA51, pACY177, pKH47, pACYC184, pUB110, pMB9, Co1E1, pSC101, pm121, RSF2124, pCR1 or RP4.

The insertion of the gag and env genes into a cloning vector is easily accomplished when both the genes and the desired cloning vehicle have been cut with the same restriction enzyme or enzymes, since complementary DNA termini are thereby produced. If this cannot be accomplished, it may be necessary to modify the cut ends that are produced by digesting back single-stranded DNA to produce blunt ends, or by

achieving the same result by filling in the single-stranded termini with an appropriate DNA polymerase. In this way, blunt-end ligation with an enzyme such as T4 DNA ligase may be carried out. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini. Such linkers may comprise specific oligonucleotide sequences that encode restriction site recognition sequences. The cleaved vector and the gag and env gene fragments may also be modified by homopolymeric tailing, as described by Morrow [Methods in Enzymology 68:3 (1979)].

Once either the gag or env gene or a fragment thereof has been inserted into an appropriate cloning vehicle, the other gene or gene fragment can be introduced into the vehicle by judicious restriction endonuclease cleavage to place the second gene or gene fragment into juxtaposition with the first, thereby creating a fusion gene. Of course if the gag and env genes are chemically synthesized, the fusion gene could be directly produced and introduced as a single DNA fragment into the cloning vehicle.

In the preferred embodiment of the present invention, the ClaI/HincII digestion fragment containing the gag gene from λ HXB-3 described above was ligated into plasmid pEV-vrf2 which had been cleaved with ClaI and PuvII to produce a recombinant expression plasmid pEV2/gag 15-512 (Figure 1, upper drawing) that directed the synthesis of a 56 Kd protein comprising gag residues 15-512. The gag sequences downstream of a BglII site near residue 437 were then replaced with env sequences in a BglII/HindIII fragment from the derivative of plasmid pEV3/env 44-640 (having residues 514-524 deleted) described above to produce plasmid pEV2/gag 15-436/env 467-640 Δ 514-524 bearing the gag/env fusion gene (Figure 1, lower drawing).

Full details of this construction are provided below in the section entitled "Example", in particular in subsections B to E. The nucleic acid sequence of the gag/env gene of the preferred embodiment [determined by the chemical cleavage method of Maxam et al., Methods in Enzymology 65:499 (1980)] and the amino acid sequence of the gag/env protein predicted therefrom are shown in Figure 2.

Many of the cloning vehicles that may be used in this invention contain one or more marker activities that may be used to select for desired transformants, such as ampicillin and tetracycline resistance in pBR322, ampicillin resistance and β -galactosidase activity in pUC8, and ampicillin resistance in pEV-vrf2. Selection of host cells into which such vectors have been inserted is greatly simplified when the host cells otherwise lack the activities contributed by the vectors.

It should be understood that the nucleotide sequences of the gag and env gene fragments inserted at a selected site in a cloning vehicle may include nucleotides which are not part of the actual structural genes. Alternatively, the gene fragments may contain only part of the complete genes. All that is required is that the gene fragments inserted into the cloning vehicle be capable of directing the production in an appropriate host organism of a polypeptide or protein having at least one antigenic determinant corresponding to the sequences of the gag and env proteins.

The selection of an appropriate host organism is affected by a number of factors known in the art. These factors include, for example, compatibility with the chosen vector, toxicity of proteins encoded by the hybrid plasmid, ease of recovery of the desired protein, expression characteristics, biosafety and costs. A balance of these factors must be struck, and it must be understood that not all hosts will be equally effective for expression of a particular recombinant DNA molecule.

Suitable host unicellular organisms which can be used in this invention include but are not limited to plant, mammalian or yeast cells and bacteria such as *Escherichia coli*, *Bacillus subtilis*, *Bacillus stearothermophilus* and *Actinomyces*. *Escherichia coli* strain MC1061 which has been described by Casadaban et al. [J. Mol. Biol. 138:179 (1980)], can be used as can be used any other strain of *E. coli* K-12 containing the plasmid pRK248clts. Plasmid pRK248clts for use in other *E. coli* K-12 strains is freely available from the American Type Culture Collection (ATCC) and has accession No. ATCC 33766. *E. coli* strain MC1061 has also been deposited at ATCC (accession No. ATCC 53338) and is also freely available upon request.

Transfer of the recombinant cloning vector into the host cell may be carried out in a variety of ways.

Depending upon the particular vector/host cell system chosen, such transfer may be effected by transformation, transduction or transfection. Once such a modified host cell is produced, the cell can be cultured and the protein expression product may be isolated from the culture.

As produced in *E. coli*, the gag/env protein is largely confined to cytoplasmic inclusion bodies (insoluble protein aggregates) of the bacterium, a fact which greatly facilitates purification of the protein. To isolate the gag/env protein product of this invention, the bacterial cells are preferably disrupted or lysed and the insoluble protein is recovered by centrifugation. Substantial purification can then be obtained by sequential washing of the precipitate with increasing concentrations of urea followed by the use of standard protein purification techniques.

For small amounts of material such as samples taken for polyacrylamide gel electrophoretic analysis, the cells can be disrupted by treatment with a detergent such as sodium dodecyl sulfate (SDS). Larger quantities of the protein are best recovered by sonication, or by other mechanically disruptive means, such as the French pressure cell.

Cell disruption could also be accomplished by chemical or enzymatic means. Since divalent cations are often required for cell membrane integrity, treatment with appropriate chelating agents such as EDTA or EGTA might prove sufficiently disruptive to facilitate the leakage of the protein from the cells. Similarly, enzymes such as lysozyme have been used to achieve the same result. That enzyme hydrolyzes the peptidoglycan backbone of the cell wall. The application of alternating freezing and thawing in conjunction with lysozyme treatment could also be employed.

Once freed from the cells, the gag/env protein may be identified in the mixture by any of the methods known in the art. For example, a radioimmunoassay or enzyme-linked immunosorbent assay could be carried out using antibodies against the protein. Preferably, the protein is identified by SDS polyacrylamide gel electrophoresis followed by Western blot or similar analysis.

5 The gag/env protein of the invention can be concentrated by precipitation with salts such as sodium or ammonium sulfate, by ultrafiltration or by the use of other methods well known to those skilled in the art. Further purification can be accomplished by conventional protein purification techniques including but not limited to gel filtration, ion-exchange chromatography, preparative disc-gel or curtain electrophoresis, isoelectric focusing, low temperature organic solvent fractionation or countercurrent distribution. 5

10 Because the gag/env protein contains antigenic determinants from two major components of the HTLV-III virus, and because this virus is the principal etiologic agent in AIDS and is immunologically related to the other viral agents which have been implicated in or associated with AIDS or ARC, the protein is a powerful diagnostic tool for the detection of antibodies against AIDS viruses in human serum. The fusion can be used for this purpose in numerous ways known in the art. 10

15 For example, the gag/env protein could be labeled in any number of ways, the labeled protein could be added to a human serum sample suspected to contain antibodies against AIDS viruses to form labeled fusion protein-antibody complexes, and the complexes thus formed could be detected by appropriate means. By way of further example, the protein could be immobilized on a solid support and then contacted with a human serum sample. Antibodies against AIDS viruses in the sample would bind to the immobilized protein, 15 and the complexes thus formed could be detected by the use of a reagent such as *Staphylococcus aureus* protein A (labeled, e.g., with Iodine-125) or a second anti-human IgG antibody (labeled, e.g., with a radioisotope or with horseradish or lactoperoxidase) after uncomplexed proteins and antibodies have been washed away. Many variations on these themes will be apparent to the skilled artisan, some of which are suggested below. 20

25 Through the use of antibodies against the gag/env protein, a variety of diagnostic tests for the presence of AIDS viruses or particles therefrom in human serum or in other biological fluids can be devised. Such antibodies can be produced by injecting a mammalian or avian animal with a sufficient amount of a vaccine formulation comprising the protein and a compatible pharmaceutical carrier to elicit the production of antibodies against the protein. The appropriate amount of the protein which would be required would be 30 known to one of skill in the art or could be determined by routine experimentation. As used in connection with this invention, the term "pharmaceutical carrier" can mean either the standard compositions which are suitable for human administration or the typical adjuvants employed in animal vaccinations. 30

Suitable adjuvants for the vaccination of animals include but are not limited to Freund's complete or incomplete adjuvant (not suitable for human or livestock use), Adjuvant 65 (containing peanut oil, mannide 35 monooleate and aluminum monostearate), and mineral gels such as aluminum hydroxide, aluminum phosphate and alum; surfactants such as hexadecylamine, octadecylamine, lysolecithin, dimethyldioctadecylammonium bromide, N₁-N-dioctadecyl-N'-N-bis(2-hydroxyethyl-propanediamine), methoxyhexadecylglycerol, and pluronic polyols; polyanions such as pyran, dextran sulfate, poly IC, polyacrylic acid, carboxypol; peptides such as muramyl dipeptide, dimethylglycine, tuftsin; and oil emulsions. 40 The gag/env protein could also be administered following incorporation into liposomes or other microcarriers, or after conjugation to polysaccharides, other proteins or other polymers. 40

Typically, the initial vaccination is followed some weeks later by one or more "booster" vaccinations, the net effect of which is the production of high titers of antibodies against the gag/env protein, which can be harvested in the usual way.

45 Of course, monoclonal antibodies against the protein could be produced through current technology to achieve the same result. Somatic cells with the ability to produce antibodies, such as B cells, may be fused with myeloma cell lines to produce hybridoma cells. These cells may be cultured in vitro or as ascites tumors indefinitely to produce large quantities of specific antibodies. Because hybridoma cells may be readily cloned, it is possible to rapidly produce large numbers of cells, all of which produce the same specific 50 antibody molecules directed to a common antigenic determinant. This exceptional uniformity in antibody production may be advantageous where the antibodies are to be used in specific diagnostic tests. 50

Lymph nodes and spleens of animals of animals primed by injection of an antigen are convenient sources of B cells, although it is equally feasible to remove these cells from unsensitized animals, and to prime them in vitro after isolation. Mouse and rat B lymphocytes are most frequently used in hybridoma production, but 55 cells from rabbits, human beings, frogs or other animals might be used instead. 55

Numerous specialized myeloma cell lines have been developed from lymphocytic tumors for use in hybridoma production [Köhler and Milstein, *European J. Immunol.* 6:511 (1976); Shulman et al., *Nature* 276:269 (1978)]. Of the many such cell lines produced, P3/X63-Ag 8, P3/NSI/1-Ag 4-1, Sp2/O-Ag14, and S194/5.XXO.BU.1 have frequently been used.

60 The fusion of the antibody-producing spleen or lymph node cells with myeloma cells to produce hybridomas is usually carried out with an excess of splenocytes or lymphocytes over myeloma cells that may be as high as 20:1 although, typically, lower ratios are used. Fusion is facilitated by the use of a fusion-promoting agent such as UV-inactivated Sendai virus or polyethylene glycol (PEG). Geffer et al. [Somatic Cell Genet. 3:231 (1977)] have reported that combining dimethyl sulfoxide with PEG further 65 enhances cell fusion. Electrical devices are also available which can fuse cells with an exceptionally high 65

degree of efficiency.

Once fusion has occurred, the hybridoma cells must be selected from the unfused parental cell strains. This selection process may be readily accomplished by culturing the cells in a medium that supports hybridoma but not parental cell growth. The somatic B cells used in the fusion have limited lifespans in culture and thus will be lost as they undergo senescence and death, but the parental myeloma cells, with indefinite culture lifespans, must be eliminated by special selection techniques.

In a commonly used system, myeloma cells lacking hypoxanthine phosphoribosyl transferase (HPRT⁻) are used. These cells lack the scavenger pathway for the reutilization of hypoxanthine free base and cannot survive if an inhibitor, such as aminopterin, is used to block the de novo purine synthetic pathways. The myeloma parental cells may thus be selected against by culturing the fusion mixture in hypoxanthine/aminopterin/thymidine (HAT) medium, while the hybridoma cells will survive due to the contribution of HPRT by the antibody-producing fusion parental cells.

After a period of selection culturing, the surviving hybridoma cells may be cloned, stocks may be grown up by standard cell culture methods, and clones producing desired specific immunoglobulins may be detected by enzyme-linked immunosorbent assay (ELISA) or by other tests, based upon the use of the antigen against which the antibodies are directed.

The anti-gag/env protein antibodies obtainable through the use of this invention may further be used for the preparation of a variety of diagnostic tests for AIDS viruses or particles therefrom. Such diagnostic systems could take the form of a radioimmunoassay, either in free solution or solid state. Alternatively, enzyme-linked immunosorbent assays could be produced, as could assays based on immunoblot analysis. These assays could be direct or indirect, with the application of a second antibody directed against the anti-gag/env protein antibodies. Numerous enzymatic activities could be coupled to the antibodies, with peroxidase, glucose oxidase, β -galactosidase and alkaline phosphatase being only a few of the possibilities.

The basic principle underlying many of these tests is that a human serum or other biological fluid sample suspected to contain AIDS viruses or fragments therefrom is reacted with a known titer of antibodies against the gag/env protein to form antigen-antibody complexes. The complexes thus formed are detected by an appropriate means.

Those skilled in the art will also recognize that there are many other ways in which anti-gag/env protein antiserum could be utilized in a diagnostic capacity, such as in one of a number of agglutination tests. In such agglutination assays, the interaction of antibodies and AIDS viruses or viral fragments may be detected using systems in which particles are coated with the anti-gag/env protein antibodies. Such particles may be latex beads, liposomes, erythrocytes, polyacrylamide beads, or any of a number of suitable polymers.

The method for the determination of AIDS virus or of antibodies against AIDS virus as described above can be conducted in suitable test kits comprising in a container the gag/env protein of the present invention or antibodies against AIDS virus elicited by the gag/env protein of the present invention.

Crowl et al. [Cell 41, 979-986 (1985)] have described that the serum of all of 50 AIDS patients tested with genetically engineered env protein was highly reactive to the protein. This was true despite the fact that half of these patients were from the west coast of the United States, and half were from the east coast. The fact that all of the sera tested were reactive to the env protein showed that the viruses producing the antibodies that thus reacted, although geographically separated and undoubtedly somewhat genetically different, must have had at least one common or conserved antigenic determinant in their envelope proteins.

The gag core protein of the AIDS retrovirus has been found to induce antibody formation in a large percentage of individuals who had previously been exposed to the virus [Montagnier et al., supra; Schüpbach et al., supra; Sarngadharan et al., supra].

Taken together, the above observations suggest that the gag/env protein of this invention, which has at least one antigenic determinant corresponding to the sequences of the gag and env proteins of which it is comprised, would be immunogenic in human beings and may be useful as an AIDS vaccine.

Thus, the gag/env protein (either produced as described herein or chemically synthesized) can be used in a vaccine formulation comprising the protein and a compatible pharmaceutical carrier. The protein can be used as purified in such formulations, or it can be made more immunogenic by modifications known in the art. For example, the protein can be converted into a highly immunogenic matrix by reaction with a cross-linking agent such as 1,3-dicyclohexylcarbodiimide. Alternatively, the protein could be covalently coupled to a highly immunogenic protein carrier molecule, either directly or with an appropriate linker molecule. Carrier molecules which could be used include, e.g., limpet hemocyanin and various bacterial toxoids (inactive toxins) such as diphtheria toxoid. Where the gag/env protein is conjugated to a bacterial toxoid, a bivalent vaccine formulation can be produced that will provide protection against both AIDS and the bacterium from which the toxoid was derived.

Routes of administration, antigen dose, number frequency of injections are all factors falling within the ordinary skill in the art.

EXAMPLE

The following is a non-limiting example illustrating the methods by which a recombinant vector encoding the gag/env protein of the HTLV-III virus can be produced. In this example, the following steps were carried out, each of which will be described in detail below:

(1) The DNA sequence encoding residues 15-512 (all but the first 14 amino-terminal residues) of the gag

gene was excised from recombinant phage clone λ HXB-3 and ligated into *E. coli* expression plasmid pEV-vrf2 to produce plasmid pEV2/gag 15-512;

(2) DNA sequences corresponding the env amino acid residues 319-331 were deleted from expression plasmid pEV3/env 44-640 by primer-directed mutagenesis to produce plasmid pEV/env 44-640 Δ 319-331;

(3) Primer-directed mutagenesis was carried out on plasmid pEV/env 44-640 Δ 319-331 to produce the deletion of nucleotides encoding amino acid residues 514-524 and plasmid pEV3/env 44-640 Δ 319-331 Δ 514-524; and

(4) A restriction endonuclease fragment of the env gene from plasmid pEV/env 44-640 Δ 319-331 Δ 514-524 encoding env residues 467-640 Δ 514-524 was ligated into cleaved plasmid pEV2/gag 15-512, thereby producing a fusion gene encoding gag residues 15-436 and env residues 467-640 Δ 514-524 in plasmid pEV2/gag 15-436/env 467-640 Δ 514-524.

At each stage of the construction plasmids were reproduced by transformation into *E. coli* strain MCI061 (pRK248clts).

15 A. General procedures for recombinant vector preparation

DNA preparation

Small scale isolation of plasmid DNA from 1 ml of saturated overnight cultures was carried out according to the procedure of Birnboim et al. [Nucleic Acids Research 7:1513 (1979)]. This procedure allows the isolation of a small quantity of DNA from a bacterial colony for analytical purposes. Larger amounts of plasmid DNA were prepared using 1-liter cultures following a standard protocol with cesium chloride centrifugation.

Conditions for enzymatic reactions

The restriction enzymes and the T4 DNA ligase used were all products of New England BioLabs, Beverly, MA. The methods and conditions for the use of these enzymes were those published by the manufacturer.

For the restriction endonucleases, a unit of activity is defined as the amount of enzyme needed to produce a complete digest of 1.0 μ g DNA in 60 minutes in a total reaction volume of 0.05 ml, with digestion carried out at 37°C. The digestion mixtures, in addition to the DNA to be cleaved, contained 100 μ g/ml bovine serum albumin and the following buffer components.

30 BglII : 100 mM NaCl, 10 mM Tris-HCl (pH 7.4), 10 mM MgCl₂ and 10 mM 2-mercaptoethanol (2-ME) 30

Clal : 50 mM NaCl, 6 mM Tris-HCl (pH 7.9) and 6 mM MgCl₂

HincII : 100 mM NaCl, 10 mM Tris-HCl (pH 7.4), 7 mM MgCl₂ and 1 mM dithiothreitol (DTT)

35 HindIII : 50 mM NaCl, 50 mM Tris-HCl (pH 8.0) and 10 mM MgCl₂ 35

HpaI : 6 mM KCl, 10 mM Tris-HCl (pH 7.4), 10 mM MgCl₂ and 1 mM DTT

40 PstI : 100 mM NaCl, 10 mM Tris-HCl (pH 7.5) and 10 mM MgCl₂ 40

PvuII : 60 mM NaCl, 6 mM Tris-HCl (pH 7.5), 6 mM MgCl₂ and 6 mM 2-ME

StuI : 100 mM NaCl, 10 mM Tris-HCl (pH 8.0), 10 mM MgCl₂ and 6 mM 2-ME

45 T4 DNA ligation was carried out at 16°C in a mixture containing the DNA and 50 mM Tris-HCl (pH 7.8), 10 mM MgCl₂, 20 mM DTT, 1.0 mM ATP and 50 μ g/ml bovine serum albumin. A unit of T4 DNA ligase activity is defined as the amount required to give 50% ligation of HindIII fragments of lambda DNA in 30 minutes at 16°C in 20 μ l of incubation mixture and a 5' DNA termini concentration of 0.12 μ M (300 μ g/ml).

Purification of DNA fragments in agarose

Following restriction endonuclease cleavage, DNA fragments for cloning were isolated by electrophoresis in 1% agarose. After visualization by 1 µg/ml ethidium bromide, slices of the gel containing desired DNA fragments were extruded through a 21 gauge needle into 4 ml of a solution containing 10 mM Tris-HCl (pH 7.4), 1 mM EDTA and 300 mM NaCl. This mixture was then frozen for 3 hours at -80°C, thawed for 30 minutes at 37°C and centrifuged at 10,000 × g for 30 minutes. The supernatant fluid was filtered through a 0.45 micron Millex filter, concentrated to 0.25 ml with sec-butanol and ethanol precipitated three times with 10 µg of E. coli tRNA (transfer RNA) as a carrier.

10

Culture media

M9CA medium contained 10 g Na₂HPO₄, 3 g KH₂PO₄, 0.5 g NaCl and 1 g NH₄Cl per liter, with 1 mM MgSO₄, 0.5% glucose and 0.5% casamino acids, adjusted to pH 7.4.

Luria Broth (LB) contained 5 g Bacto-yeast extract, 10 g Bacto-tryptone and 10 g NaCl per liter, adjusted to pH 7.5.

The antibiotics tetracycline and ampicillin were added to final concentrations of 15 and 50 µg/ml, respectively, were indicated.

Transformation and isolation of recombinants

The transformation of E. coli strain MCI061 (pRK248clts) was carried out using a modification of the protocol of Kushner [in Genetic Engineering, eds. Boyer et al., Elsevier/North-Holland, Amsterdam, p. 17 (1978)], essentially as follows.

Two-hundred ml of the bacterial cells were grown at 30°C in LB to an O.D.₆₀₀ of between 0.5 and 1.0, after which the cells were collected by centrifugation at 6,000 × g for 5 minutes at 4°C and resuspended in 50 ml of a solution containing 10 mM morpholinopropane sulfonic acid (MOPS; pH 7.0) and 10 mM RbCl. The cells were again collected by centrifugation and resuspended in 30 ml of a solution containing 10 mM MOPS (pH 6.5), 50 mM CaCl₂ and 10 mM RbCl. After incubation at 0°C for 30 minutes, the cells were collected, resuspended in 6 ml of 10 mM MOPS (pH 6.5) with 50 mM CaCl₂, 10 mM RbCl and 15% glycerol, aliquoted into 40 Eppendorf tubes (300 µl/tube) and frozen at -80°C.

Transformation was performed by thawing a 100 µl aliquot of the cells and incubating for 30, 2 and 2 minutes at 0°C, 37° and 0°C, respectively in the presence of a 10 µl sample of ligation mixture containing about 100 ng of DNA and adding 0.1 to 0.5 ml of LB to the tube. The tube was then incubated at 22°C for 60 minutes, after which 200 µl of the cell suspension were spread onto an LB plate containing ampicillin and incubated at 30°C for 20 hours.

35

Cell growth and induction of gene expression

Cultures of E. coli MCI061 containing plasmid pRK248clts and an expression plasmid were grown in M9CA medium to mid-log phase at 30°C and then transferred to 42°C to inactivate the λ P_L repressor. After a 2 hour incubation at 42°C, cells from 1 ml of the induced culture were collected by centrifugation and resuspended in 40 TG buffer containing 10 mM Tris-HCl (pH 7.4) and 10% glycerol in preparation for analysis.

SDS polyacrylamide gel electrophoresis and western blot analysis

Induced cells resuspended in Tris-glycine (TG) buffer were mixed with an equal volume of 2x sample buffer [Laemmli, Nature 227:680 (1970)], incubated at 95°C for 5 minutes and subjected to SDS polyacrylamide gel electrophoresis in 12.5% gels as described by Laemmli. Following electrophoresis, the proteins from the gel were electroblotted onto a 0.1 micron nitrocellulose membrane for 6 hours at 95 volts in 12.5 mM Tris and 96 mM glycine with 20% methanol and 0.01% SDS at pH 7.5. Western blot analysis was then carried out as described by Towbin et al. [Proc. Natl. Acad. Sci. U.S.A. 76:4350 (1979)].

Primer-directed mutagenesis

Primer-directed site specific mutagenesis was performed according to the methods described by Morinaga et al. [Biotechnology 2:636 (1984)]. Synthetic oligonucleotides used to carry out the mutagenesis procedure were prepared by phosphite methodology [Beaucage et al., Tetrahedron Lett. 22:1859 (1981); Matteucci et al., J. Am. Chem. Soc. 103: 3185 (1981)] using an automated synthesizer and purified by polyacrylamide gel electrophoresis by the method of Maxam et al., [Methods in Enzymology 65:499 (1980)].

Colony hybridizations

Colony hybridizations were performed by the method of Grunstein et al. [Proc. Natl. Acad. Sci. U.S.A. 72:3961 (1975)]. The same oligonucleotide used for primer-directed site specific mutagenesis was used as a probe for the hybridizations after 5' end labeling with ³²P-(γ-ATP using polynucleotide kinase as described by Maniatis et al. [Cell 15:687 (1978)]).

B. Construction of plasmid pEV2/gag 15-512

As noted above, construction of a final expression plasmid expression the gag/env fusion protein was initiated by construction of a plasmid (pEV2/gag 15-512) containing nucleotides encoding all but the first 14

amino-terminal residues. Some of the nucleotides encoding the carboxylterminal gag residues were then replaced by env sequences to obtain the final fusion product.

To make plasmid pEV2/gag 15-512, the DNA sequence encoding residues 15-512 of the gag protein was obtained from 50 µg of recombinant phage lambda clone λHXB-3 containing the HTLV-III proviral genome by cleavage with 50 units of *Cl*I and 50 units of *H*incII for 120 minutes at 37°C to produce a 1700 bp fragment. This DNA fragment was isolated by preparative agarose gel electrophoresis and resuspended in 0.1x TE buffer [1 mM Tris-HCl (pH 7.4) with 0.1 mM EDTA] to a final concentration of 0.03 pmole/µl.

To receive the gag DNA fragment, 2 µg of the *E. coli* expression plasmid pEV-vrf2 were cleaved with 5 units of *Cl*I and 5 units of *P*vull for 60 minutes at 37°C, and a 1700 bp fragment containing the λ P_L promoter was isolated by electrophoresis in 1% agarose gel and resuspended after ethanol precipitation to a final concentration of 0.03 pmole/µl.

Plasmid pEV-vrf2 used in this construction is a derivative of readily available plasmid pBR322 [ATCC 31344]. The construction of plasmid pEV-vrf2 has been described in detail by Crowl et al. [Gene 38:31 (1985)]. Recombinant phage lambda clone λHXB-3 used in this construction has been described by Shaw et al. [Science 226:1165: (1984)]. This clone was obtained using standard recombinant DNA techniques from the HTLV-III infected H-9 cell line described above. An HTLV-III infected human cell line designated H9/HTLV-III B which is suitable for use in this invention has been deposited with the American Type Culture Collection and assigned accession No. CRL8543. Since Shaw et al. have published the sequence of the HTLV-III genome, a DNA probe can easily be constructed using those data which can be used to isolate the genome from H-9 or from any other line capable of propagating the virus.

Three-hundredths (300) pmole of the gag/*Cl*I-*H*incII fragment were mixed with 0.03 pmole of the pEV-vrf2/*Cl*I-*P*vull fragment and ligated with 200 units of T4 DNA ligase for 18 hours at 15°C in a final volume of 10 µl. The ligation product was then transformed into *E. coli* strain MCI061 (pRK248clts), and transformants were selected by growth on LB agar plates with ampicillin after incubation at 30°C for 18 hours. The recombinant plasmid DNAs were analyzed for correct restriction fragment size following cleavage with *B*glII, *P*stI or *H*indIII. Isolates positive by DNA size analysis were then evaluated for synthesis of the gag precursor polypeptide by SDS polyacrylamide gel electrophoresis and Western blot analysis.

Cultures harboring plasmid pEV2/gag 15-512 were induced at 40°C, and duplicate samples of the induced cells were prepared for analysis by SDS polyacrylamide gel electrophoresis. After electrophoresis, the gel was bisected, and half of the gel was stained with Coomassie brilliant blue, while the other side of the gel was subjected to electroblotting and Western blot analysis using anti-gag antibodies.

The analysis showed that the induced cells produced proteins which migrated as two major bands in the gels having apparent molecular weights of about 56 and 53 Kd. The size of the complete gag 15-512 protein is about 56 Kd. Both of the major proteins reacted with the anti-gag antibodies. A number of minor lower molecular weight proteins which were reactive with the antibodies were also observed.

C. Construction of plasmid pEV3/env 44-640 Δ 319-331

The env sequences present in the final exemplary plasmid of this invention were processed in two stages (described in this section and in Section D, below), each of which involved the deletion of specific short nucleotide sequences by primer-directed site specific mutagenesis. The first of these deletions (described in this section) was required to produce plasmid pEV3/env 44-640 Δ 319-331 Δ 514-524 (Section D).

The expression plasmid pEV3/env 44-640, the construction of which from λHXB-3 and the pEV-vrf plasmids has been described by Crowl et al. [Cell 41:979 (1985)], directs the synthesis of a 68 Kd HTLV-III env specific protein in *E. coli*. DNA sequences corresponding to env amino acid residues 319-331 were deleted by primer-directed mutagenesis using an 18-mer synthetic oligonucleotide having the sequence 5' GCA TTT GTT AAC ATT AGT 3'. This oligonucleotide was designed to complement env sequences so as to join nucleotides encoding residue 318 to those encoding residue 332. As a result of bringing these sequences together, a new unique *H*paI site was introduced into the plasmid DNA, while 39 bp were deleted. The *S*tul and *H*indIII sites in plasmid pEV3/env 44-640 were used to form the "gap" for the heteroduplex molecule.

DNA from isolated colonies which were positive for hybridization to the ³²P-labeled synthetic oligonucleotide during colony screening were transformed into MCI061 (pRK248clts) and analyzed for the presence of the new, unique *H*paI site.

D. Construction of plasmid pEV3/env 44-640 Δ 319-331 Δ 514-524

A second deletion within the env coding sequences was created by primer directed mutagenesis using a synthetic oligonucleotide having the sequence 5' AGA GCA GTG GCA GCA GGA 3'. This oligonucleotide positioned sequences encoding residue 513 of the env protein adjacent to those encoding residue 525, thereby facilitating the deletion of the nucleotides encoding residues 514-524. This deletion was produced in the plasmid using the restriction sites *H*paI and *H*indIII to create a single-stranded gap within the env region.

After re-transformation, DNA from positive isolates identified by the ³²P-labeled oligonucleotide probe was analyzed for the 33 bp deletion by restriction cleavage with *H*paI and *H*indIII followed by electrophoresis in 1% agarose. This deletion was also confirmed by DNA sequencing following the chemical cleavage method of Maxam and Gilbert [Methods in Enzymology 65:499 (1980)].

As previously noted, the Δ 514-524 deletion produces a significant increase in the expression of env.

E. Construction of plasmid pEV2/gag 15-436/env 467-640 Δ 514-524

Two μ g of pEV2/gag 15-512 were doubly digested with either 5 units of ClaI and 4 units of BglII to produce about a 1300 bp fragment encoding gag residues 15-436 or with 10 units of PstI and 5 units of ClaI to produce about a 1 Kb fragment containing the λ P_L promoter. Three-tenths μ g of pEV3/env 44-640 Δ 319-331 Δ 514-524 were restricted with 10 units of PstI and 4 units of BglII to produce about a 4 Kb fragment encoding env residues 467-640 Δ 514-524. The various DNA fragments thus produced were separated in 1% agarose and recovered as previously described.

Three-hundredths pmole of each of the isolated DNA fragments were mixed and ligated for 18 hours at 15°C in the presence of 200 units of T4 DNA ligase. The products of the ligation mixture were then transformed into MC1061 (pRK248clts), and transformants were selected on LB agar plates with ampicillin. Plasmid DNA was prepared from unique colonies and analyzed for correct restriction fragment size following digestion with PvuII.

Eleven of 12 isolates were positive by DNA analysis for the expected 3505 and 2882 bp PvuII fragments. Two positive isolates were further evaluated for synthesis of the gag/env fusion protein. These cultures were induced, and cell samples were taken for analysis by SDS polyacrylamide gel electrophoresis, electroblotting and Western blots, with the results shown in Figure 3.

Panel 1 in Figure 3 shows Coomassie blue-stained total cell proteins from cells harboring the recombinant plasmid carrying the gag/env fusion gene (g/e) and from control cells (c). Panels 2 and 3 show the results of duplicate samples subjected to Western blot analysis using rabbit polyclonal antibodies against a synthetic peptide corresponding to env residues 500-511 (panel 2) or using sheep polyclonal antibodies against gag protein p24 which is commercially available [panel 3; see Dowbenko et al., Proc. Natl. Acad. Sci. U.S.A. 82:7748 (1985) for description of p24 protein]. In Figure 3, the immune complexes in panels 2 and 3 were visualized by a second antibody labeled with horseradish peroxidase, and the mobilities of molecular weight standards (in Kd) are indicated. The positions of the gag/env protein bands in the gels are denoted by arrows.

Many modifications and variations of this invention may be made without departing from its spirit and scope, as will become apparent to those skilled in the art. For example, nucleic acid substitutions could be made in the gene coding for the gag/env protein of the invention (using the sequence data contained herein as a reference) and a somewhat different (but functionally equivalent) fusion protein could be produced therefrom. Such an altered product would still be encompassed by this invention as long as it had at least one antigenic determinant corresponding to the sequences of a gag and env protein of an HTLV-III virus. Similarly, the amino acid sequence of the protein itself could be directly manipulated, with the same result. The specific embodiments described herein are offered by way of example only, and the invention is limited only by the terms of the appended claims.

35 CLAIMS

1. A protein having an amino acid sequence corresponding to at least one antigenic determinant of a HTLV-III gag protein and of a HTLV-III env protein.

2. The protein according to claim 1 of the amino acid sequence

40	Met	Asn	Arg	Ile	Arg	Ile	His	Arg	Trp	Glu	Lys	Ile	Arg	Leu	Arg
	Pro	Gly	Gly	Lys	Lys	Lys	Tyr	Lys	Leu	Lys	His	Ile	Val	Trp	Ala
	Ser	Arg	Glu	Leu	Glu	Arg	Phe	Ala	Val	Asn	Pro	Gly	Leu	Leu	Glu
	Thr	Ser	Glu	Gly	Cys	Arg	Gln	Ile	Leu	Gly	Gln	Leu	Gln	Pro	Ser
45	Leu	Gln	Thr	Gly	Ser	Glu	Glu	Leu	Arg	Ser	Leu	Tyr	Asn	Thr	Val
	Ala	Thr	Leu	Tyr	Cys	Val	His	Gln	Arg	Ile	Glu	Ile	Lys	Asp	Thr
	Lys	Glu	Ala	Leu	Asp	Lys	Ile	Glu	Glu	Glu	Gln	Asn	Lys	Ser	Lys
	Lys	Lys	Ala	Gln	Gln	Ala	Ala	Ala	Asp	Thr	Gly	His	Ser	Ser	Gln
	Val	Ser	Gln	Asn	Tyr	Pro	Ile	Val	Gln	Asn	Ile	Gln	Gly	Gln	Met
50	Val	His	Gln	Ala	Ile	Ser	Pro	Arg	Thr	Leu	Asn	Ala	Trp	Val	Lys
	Val	Val	Glu	Glu	Lys	Ala	Phe	Ser	Pro	Glu	Val	Ile	Pro	Met	Phe
	Ser	Ala	Leu	Ser	Glu	Gly	Ala	Thr	Pro	Gln	Asp	Leu	Asn	Thr	Met
	Leu	Asn	Thr	Val	Gly	Gly	His	Gln	Ala	Ala	Met	Gln	Met	Leu	Lys
	Glu	Thr	Ile	Asn	Glu	Glu	Ala	Ala	Glu	Trp	Asp	Arg	Val	His	Pro
55	Val	His	Ala	Gly	Pro	Ile	Ala	Pro	Gly	Gln	Met	Arg	Glu	Pro	Arg
	Gly	Ser	Asp	Ile	Ala	Gly	Thr	Thr	Ser	Thr	Leu	Gln	Glu	Gln	Ile
	Gly	Trp	Met	Thr	Asn	Asn	Pro	Pro	Ile	Pro	Val	Gly	Glu	Ile	Tyr
	Lys	Arg	Trp	Ile	Ile	Leu	Gly	Leu	Asn	Lys	Ile	Val	Arg	Met	Tyr
	Ser	Pro	Thr	Ser	Ile	Leu	Asp	Ile	Arg	Gln	Gly	Pro	Lys	Glu	Pro
60	Phe	Arg	Asp	Tyr	Val	Asp	Arg	Phe	Tyr	Lys	Thr	Leu	Arg	Ala	Glu
	Gln	Ala	Ser	Gln	Glu	Val	Lys	Asn	Trp	Met	Thr	Glu	Thr	Leu	Leu
	Val	Gln	Asn	Ala	Asn	Pro	Asp	Cys	Lys	Thr	Lie	Leu	Lys	Ala	Leu
	Gly	Pro	Ala	Ala	Thr	Leu	Glu	Glu	Met	Met	Thr	Ala	Cys	Gln	Gly
	Val	Gly	Gly	Pro	Gly	His	Lys	Ala	Arg	Val	Leu	Ala	Glu	Ala	Met
65	Ser	Gln	Val	Thr	Asn	Thr	Ala	Thr	Ile	Met	Met	Gln	Arg	Gly	Asn

	Phe	Arg	Asn	Gln	Arg	Lys	Met	Val	Lys	Cys	Phe	Asn	Cys	Gly	Lys	
	Glu	Gly	His	Thr	Ala	Arg	Asn	Cys	Arg	Ala	Pro	Arg	Lys	Lys	Gly	
	Cys	Trp	Lys	Cys	Gly	Lys	Glu	Gly	His	Gln	Met	Lys	Asp	Cys	Thr	
	Glu	Arg	Gln	Ala	Asn	Phe	Leu	Gly	Lys	Ile	Phe	Arg	Pro	Gly	Gly	
5	Gly	Asp	Met	Arg	Asp	Asn	Trp	Arg	Ser	Glu	Leu	Tyr	Lys	Tyr	Lys	5
	Val	Val	Lys	Ile	Glu	Pro	Leu	Gly	Val	Ala	Pro	Thr	Lys	Ala	Lys	
	Arg	Arg	Val	Val	Gln	Arg	Glu	Lys	Arg	Ala	Val	Ala	Ala	Gly	Ser	
	Thr	Met	Gly	Ala	Ala	Ser	Met	Thr	Leu	Thr	Val	Gln	Ala	Arg	Gln	
	Leu	Leu	Ser	Gly	Ile	Val	Gln	Gln	Gln	Asn	Asn	Leu	Leu	Arg	Ala	
10	Ile	Glu	Ala	Gln	Gln	His	Leu	Leu	Gln	Leu	Thr	Val	Trp	Gly	Ile	10
	Lys	Gln	Leu	Gln	Ala	Arg	Ile	Leu	Ala	Val	Glu	Arg	Tyr	Leu	Lys	
	Asp	Gln	Gln	Leu	Leu	Gly	Ile	Trp	Gly	Cys	Ser	Gly	Lys	Leu	Leu	
	Cys	Thr	Thr	Ala	Val	Pro	Trp	Asn	Ala	Ser	Trp	Ser	Asn	Lys	Ser	
	Leu	Glu	Gln	Ile	Trp	Asn	His	Thr	Thr	Trp	Met	Glu	Trp	Asp	Arg	
15	Glu	Ile	Asn	Asn	Tyr	Thr	Ser	Phe	Asn	Ala	Val	Val	Tyr	His	Ser	15

or a functional part of equivalent thereof.

3. A protein according to claim 1 or 2 in essentially pure form.

4. A DNA sequence coding for a protein as claimed in any one of claims 1 to 3.

20 5. The DNA sequence according to claim 4 in which the DNA sequence comprises all or part of the nucleic acid sequence 20

	ATGAATAGAA	TTCGGATCCA	TCGATGGGAA	AAAATTCGGT	TAAGGCCAGG	
	GGGAAAGAAA	AAATATAAAT	TAAAACATAT	AGTATGGGCA	AGCAGGGAGC	
25	TAGAACGATT	CGCAGTTAAT	CCTGGCCTGT	TAGAAACATC	AGAAGGCTGT	25
	AGACAAATAC	TGGGACAGCT	ACAACCATCC	CTTCAGACAG	GATCAGAAGA	
	ACTTAGATCA	TTATATAATA	CAGTAGCAAC	CCTCTATTGT	GTGCATCAAA	
	GGATAGAGAT	AAAAGACACC	AAGGAAGCTT	TAGACAAGAT	AGAGGAAGAG	
	CAAAACAAAA	GTAAGAAAAA	AGCACAGCAA	GCAGCAGCTG	ACACAGGACA	
30	CAGCAGTCAG	GTCAGCCAAA	ATTACCCTAT	AGTGCAGAAC	ATCCAGGGGG	30
	AAATGGTACA	TCAGGCCATA	TCACCTAGAA	CTTTAAATGC	ATGGGTAAAA	
	GTAGTAGAAG	AGAAGGCTTT	CAGCCCAGAA	GTAATACCCA	TGTTTTTCAGC	
	ATTATCAGAA	GGAGCCACCC	CACAAGATTT	AAACACCATG	CTAAACACAG	
	TGGGGGGACA	TCAAGCAGCC	ATGCAAATGT	TAAAAGAGAC	CATCAATGAG	
35	GAAGCTGCAG	AATGGGATAG	AGTACATCCA	GTGCATGCAG	GGCCTATTGC	35
	ACCAGGCCAG	ATGAGAGAAC	CAAGGGAAG	TGACATAGCA	GGAACCTACTA	
	GTACCTTTCA	GGAACAAATA	GGATGGATGA	CAAATAATCC	ACCTATCCCA	
	GTAGGAGAAA	TTTATAAAAG	ATGGATAATC	CTGGGATTAA	ATAAAATAGT	
	AAGAATGTAT	AGCCCTACCA	GCATTCTGGA	CATAAGACAA	GGACCAAAAG	
40	AACCTTTTAG	AGACTATGTA	GACCGTTTCT	ATAAACTCT	AAGAGCCGAG	40
	CAAGCTTCAC	AGGAGGTAAG	AAATTGGATG	ACAGAAACCT	TGTTGGTCCA	
	AAATGCGAAC	CCAGATTGTA	AGACTATTTT	AAAAGCATTG	GGACCAGCGG	
	CTACACTAGA	AGAAATGATG	ACAGCATGTC	AGGGAGTAGG	AGGACCCGGC	
	CATAAGGCAA	GAGTTTTGGC	TGAAGCAATG	AGCCAAGTAA	CAAATACAGC	
45	TACCATAATG	ATGCAGAGAG	GCAATTTTAG	GAACCAAAGA	AAGATGGTTA	45
	AGTGTTTCAA	TTGTGGCAAA	GAAGGGCACA	CAGCCAGAAA	TTGCAGGGCC	
	CCTAGGAAAA	AGGGCTGTTG	GAAATGTGGA	AAGGAAGGAC	ACCAAATGAA	
	AGATTGTACT	GAGAGACAGG	CTAATTTTTT	AGGGAAGATC	TTCAGACCTG	
	GAGGAGGAGA	TATGAGGGAC	AATTGGAGAA	GTGAATTATA	TAAATATAAA	
50	GTAGTAAAAA	TTGAACCATT	AGGAGTAGCA	CCCACCAAGG	CAAAGAGAAG	50
	AGTGGTGCAG	AGAGAAAAAA	GAGCAGTGGC	AGCAGGAAGC	ACTATGGGCG	
	CAGCGTCAAT	GACGCTGACG	GTACAGGCCA	GACAATTATT	GTCTGGTATA	
	GTGCAGCAGC	AGAACAATTT	GCTGAGGGCT	ATTGAGGCGC	AACAGCATCT	
	GTTGCAACTC	ACAGTCTGGG	GCATCAAGCA	GCTCAGGCA	AGAATCCTGG	
55	CTGTGGAAAG	ATACCTAAAG	GATCAACAGC	TCCTGGGGAT	TTGGGGTTGC	55
	TCTGGAAAAC	TACTTTGCAC	CACTGCTGTG	CCTTGGAATG	CTAGTTGGAG	
	TAATAAATCT	CTGGAACAGA	TTTGGAATCA	CACGACGTGG	ATGGAGTGGG	
	ACAGAGAAAT	TAACAATTAC	ACAAGCTTTA	ATGCGGTAGT	TTATCACAGT	
60	TAA					60

or a functional equivalent thereof.

6. A recombinant vector comprising a DNA sequence according to claim 4 or 5 capable of directing expression of said DNA sequence in a compatible unicellular host organism.

7. A recombinant vector according to claim 6 which is plasmid pEV2/gag15-436/env 467-640 Δ 514-524.

65 8. A unicellular organism containing a recombinant vector as claimed in claim 6 or 7. 65

9. A unicellular organism according to claim 8 which is a procaryotic cell.
10. A unicellular organism according to claim 9 which is an Escherichia coli cell.
11. A unicellular organism according to claim 10 which is Escherichia coli MC 1061 cell.
12. A unicellular organism according to claim 8 which is a eucaryotic cell.
- 5 13. A protein according to any one of claims 1 to 3 as constituent of a vaccine. 5
14. A protein according to any one of claims 1 to 3 as antigen.
15. A process for producing a protein as claimed in any one of claims 1 to 3, comprising
 - (a) culturing a unicellular organism containing a recombinant vector as claimed in claim 6 or 7 under appropriate conditions of growth so that said protein is expressed; and
- 10 16. A process according to claim 15 wherein the unicellular organism is an E. coli cell. 10
17. A process according to claim 16 wherein the recombinant vector is plasmid pEV2/gag 15-436/env 467-640 Δ 514-524.
18. A process for preparing a unicellular organism as claimed in any one of claims 8 to 12, characterized
- 15 by introduction of a recombinant vector as claimed in claim 6 or 7 into a unicellular organism. 15
19. A process according to claim 18 in which the recombinant vector is introduced into the unicellular organism by transformation.
20. A process according to claim 18 in which the recombinant vector is introduced into the unicellular organism by transduction.
- 20 21. A process according to claim 18 in which the recombinant vector is introduced into the unicellular organism by transfection. 20
22. A process for detecting the presence of antibodies against AIDS viruses in human serum, comprising:
 - (a) labeling a protein of any one of claims 1-3;
 - (b) reacting the labeled protein of step (a) with a human serum sample and, allowing labeled protein-
- 25 antibody complexes to form in the reaction mixture; and 25
- (c) determining the labeled protein-antibody complexes of step (b).
23. A process for detecting the presence of antibodies against AIDS viruses in human serum, comprising:
 - (a) immobilizing a protein of claims 1-3 on a solid support;
 - (b) contacting a human serum sample with the immobilized protein of step (a) and allowing immobilized
- 30 protein-antibody complexes to form; 30
- (c) washing away unbound protein and antibodies from the complexes of step (b); and
- (d) determining such complexes by the addition of a reagent selected from the group consisting of labeled Staphylococcus aureus protein A and a labeled second anti-human IgG antibody.
24. A process for detecting the presence of AIDS viruses or fragments therefrom in human serum or other
- 35 biological fluid, comprising: 35
- (a) reacting a human serum or other biological fluid sample with a known titer of antibodies raised against a protein as claimed in any one of claims 1 to 3;
- (b) allowing the antibodies and sample to interact to form antigen-antibody complexes in the reaction mixture; and
- 40 (c) detecting the antigen-antibody complexes of step (b). 40
25. The process according to claim 24 in which the antibodies are enzyme-labeled, and the antigen-antibody complexes formed in the reaction mixture are detected by enzyme-linked immunosorbent assay.
26. The process according to claim 24 in which a known amount of a protein of claims 1-3 labeled with a radioactive label is added to the serum or other biological fluid sample, and the antigen-antibody complexes
- 45 formed in the reaction mixture are detected by radioimmunoassay. 45
27. A process for the preparation of a vaccine comprising mixing a protein of claims 1-3 with a physiologically acceptable carrier.
28. A process for the preparation of antibodies against AIDS viruses comprising injecting into a mammalian or avian animal a sufficient amount of a protein of claims 1-3 to elicit the production of antibodies
- 50 against said protein and recovering said antibodies from the serum of said animals. 50
29. A vaccine formulation comprising a protein of claims 1-3 and a compatible pharmaceutical carrier.
30. Antibodies raised against a protein according to claims 1-3.
31. The antibodies of claim 30 which are monoclonal antibodies.
32. The use of a protein according to any one of claims 1 to 3 for the preparation of a protective immuniza-
- 55 tion vaccine. 55
33. The use of a protein according to any one of claims 1 to 3 for the preparation of antibodies against AIDS viruses.
34. The use of a protein according to any one of claims 1 to 3 for detecting the presence of antibodies against AIDS viruses in human serum.
- 60 35. A protein as claimed in any one of claims 1 to 3 whenever prepared by a process as claimed in claim 15. 60
36. A unicellular organism as claimed in any one of claims 8 to 12 whenever prepared by a process as claimed in any one of claims 18 to 21.
37. Antibodies as claimed in claim 30 or 31 whenever prepared by a process as claimed in claim 28.
- 65 38. A vaccine as claimed in claim 29 whenever prepared by a process as claimed in claim 27. 65

39. A test kit for the determination of antibodies against AIDS virus comprising in a container a protein according to any one of claims 1-3.
40. A test kit for the determination of AIDS virus comprising in a container antibodies against AIDS virus elicited by a protein according to any one of claims 1-3.

Printed for Her Majesty's Stationery Office by Croydon Printing Company (UK) Ltd, 8/87, D8991685.
Published by The Patent Office, 25 Southampton Buildings, London WC2A 1AY, from which copies may be obtained.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.